ARTBIO, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://artbio.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Early Phase 1:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Early Phase 1
1 (50.0%)Not Applicable
1 (50.0%)Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Not Applicable
Recruiting
- Conditions
- Prostate Cancer (CRPC)Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2025-10-09
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- ARTBIO Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT07214961
- Locations
- 🇺🇸
BAMF Health, Grand Rapids, Michigan, United States
🇺🇸Washington University, St Louis, Missouri, United States
🇺🇸XCancer, 17607 Gold Plaza, Omaha, Nebraska, United States
Phase 0/1 Study of 212Pb-NG001 in mCRPC
Early Phase 1
Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- ARTBIO Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT05725070
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
News
No news found